Adarx Pharmaceuticals, Inc.
Clinical trials sponsored by Adarx Pharmaceuticals, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New siRNA drug ADX-626 tested in humans for first time Results expected Jan 2027 (estimated)
-
New Gene-Targeting drug could change how we treat high blood pressure
Disease control OngoingThis early-stage study tests a new drug called ADX-850 in 28 people with mild to moderate high blood pressure. The drug uses siRNA technology to target genes involved in blood pressure regulation. The main goal is to check safety and how the drug moves through the body, with a se…
Phase 1 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for swelling disorder: experimental drug enters human trials
Disease control OngoingThis study tests a new drug called ADX-324 for hereditary angioedema (HAE), a rare genetic condition that causes sudden, severe swelling in the body. The trial has two parts: first, a small group of healthy volunteers will receive the drug to check its safety and how the body pro…
Phase 1/2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC